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Summary
Background The level of evidence for HIV transmission risk through condomless sex in serodifferent gay couples with 
the HIV-positive partner taking virally suppressive antiretroviral therapy (ART) is limited compared with the evidence 
available for transmission risk in heterosexual couples. The aim of the second phase of the PARTNER study 
(PARTNER2) was to provide precise estimates of transmission risk in gay serodifferent partnerships.
Methods The PARTNER study was a prospective observational study done at 75 sites in 14 European countries. 
The first phase of the study (PARTNER1; Sept 15, 2010, to May 31, 2014) recruited and followed up both heterosexual 
and gay serodifferent couples (HIV-positive partner taking suppressive ART) who reported condomless sex, whereas 
the PARTNER2 extension (to April 30, 2018) recruited and followed up gay couples only. At study visits, data 
collection included sexual behaviour questionnaires, HIV testing (HIV-negative partner), and HIV-1 viral load testing 
(HIV-positive partner). If a seroconversion occurred in the HIV-negative partner, anonymised phylogenetic analysis 
was done to compare HIV-1 pol and env sequences in both partners to identify linked transmissions. Couple-years of 
follow-up were eligible for inclusion if condomless sex was reported, use of pre-exposure prophylaxis or post-
exposure prophylaxis was not reported by the HIV-negative partner, and the HIV-positive partner was virally 
suppressed (plasma HIV-1 RNA <200 copies per mL) at the most recent visit (within the past year). Incidence rate of 
HIV transmission was calculated as the number of phylogenetically linked HIV infections that occurred during 
eligible couple-years of follow-up divided by eligible couple-years of follow-up. Two-sided 95% CIs for the incidence 
rate of transmission were calculated using exact Poisson methods.
Findings Between Sept 15, 2010, and July 31, 2017, 972 gay couples were enrolled, of which 782 provided 1593 eligible 
couple-years of follow-up with a median follow-up of 2·0 years (IQR 1·1–3·5). At baseline, median age for HIV-
positive partners was 40 years (IQR 33–46) and couples reported condomless sex for a median of 1·0 years 
(IQR 0·4–2·9). During eligible couple-years of follow-up, couples reported condomless anal sex a total of 
76 088 times. 288 (37%) of 777 HIV-negative men reported condomless sex with other partners. 15 new HIV 
infections occurred during eligible couple-years of follow-up, but none were phylogenetically linked within-couple 
transmissions, resulting in an HIV transmission rate of zero (upper 95% CI 0·23 per 100 couple-years of follow-up).
Interpretation Our results provide a similar level of evidence on viral suppression and HIV transmission risk for 
gay men to that previously generated for heterosexual couples and suggest that the risk of HIV transmission in 
gay couples through condomless sex when HIV viral load is suppressed is effectively zero. Our findings support 
the message of the U=U (undetectable equals untransmittable) campaign, and the benefits of early testing and 
treatment for HIV.
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Introduction
Early evidence of a strong link between the HIV 
viral load of an HIV-positive partner and the risk of 
transmission to an HIV-negative partner came from 
observational studies in serodifferent heterosexual 
couples.1–5 Evidence from a randomised study of risk of 
HIV transmission in the context of virally suppressive 
antiretroviral therapy (ART) in heterosexual couples was 
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provided by the HPTN 052 trial,6 which reported a 
96% reduction in linked transmissions in couples 
assigned to early (immediate) ART compared with couples 
assigned to delayed therapy. Continued follow-up in 
HPTN 052 from 2011 to 2016, after all participants were 
offered ART, showed durability of the effect of ART; 
however, only 2% of couples were men who have sex with 
men (MSM).7 Self-reported condom use was also high; 
participants reported not using condoms for a total of only 
63·4 couple-years of follow-up.6
The first phase of the PARTNER study (PARTNER1) 
estimated the risks for different types of sex and in a 
broader population. The study reported no linked trans-
missions in 888 serodifferent couples (548 heterosexual 
and 340 gay couples) who reported condomless pene-
trative sex during 1238 couple-years of follow-up when 
the HIV-positive partner was on virally suppressive ART.8 
PARTNER1 reported on 439 couple-years of follow-up 
in serodifferent gay couples, with zero transmissions 
reported. However, because of the lower number of 
couple-years of follow-up accumulated for gay couples 
than for heterosexual couples, the upper 95% CI limit for 
the transmission rate for gay men was relatively high 
(0·84 per 100 couple-years of follow-up), almost double 
that for heterosexual couples (0·46 per 100 couple-years 
of follow-up). These results equated to an upper limit of 
risk of one infection per 119 couple-years of follow-up for 
gay couples compared with one infection per 217 couple-
years of follow-up for heterosexual couples and was 
arguably insufficient to provide the level of evidence 
required to support ART as a fully effective HIV 
prevention inter vention in MSM.
The Opposites Attract observational study9 also reported 
zero cases of HIV transmission in MSM couples during 
232 couple-years of follow-up when condomless anal 
intercourse was reported, the HIV-positive partner was 
virally suppressed, and the HIV-negative partner did not 
use pre-exposure prophylaxis (PrEP), with a fairly high 
upper 95% CI limit of 1·59 per 100 couple-years of follow-
up for transmission rate.
The primary aim of the second phase of the PARTNER 
study (PARTNER2) was to produce a similar level 
of evidence for transmission risk through condomless 
anal sex between men with suppressive ART (defined 
as HIV-1 RNA viral load <200 copies per mL) to that 
generated for heterosexual couples in PARTNER1.
Methods
Study design and participants
The PARTNER study was an observational multicentre 
study of serodifferent couples who before enrolment 
were not always using condoms, and in which the HIV-
positive partner was on ART. Phase 1 of the study 
recruited and followed up both heterosexual and gay 
serodifferent couples from Sept 15, 2010, to May 31, 2014.8 
From June 1, 2014, to July 31, 2017, the second phase of 
the study recruited gay male serodifferent couples only. 
The methods for the PARTNER study and results of 
the first phase have been published previously.8,10
From Sept 15, 2010, to July 31, 2017, we recruited 
serodifferent gay male couples from 75 clinical sites in 
14 European countries. Participating clinic staff asked 
HIV-positive patients on ART if they had recent 
condomless sex with an HIV-negative partner and if they 
Research in context
Evidence before this study
To review previous evidence on the effect of antiretroviral 
therapy (ART) on risk of HIV transmission, we searched 
PubMed for articles published in English from Jan 1, 2000, 
to Nov 7, 2018, using the MeSH terms “HIV infection” and 
“transmission” and “antiretroviral therapy” or “ART” and 
“men who have sex with men” or “gay or heterosexual” or 
“serodiscordant” or “serodifferent”. Previous studies, including 
one randomised controlled trial and several observational 
studies, provided estimates of risk of HIV transmission through 
sexual intercourse in the context of virally suppressive ART. 
The bulk of the evidence was in heterosexual serodifferent 
couples and variable levels of condom use were reported in 
many studies. Some evidence on transmission risk in gay men 
was provided in the first phase of the PARTNER study and in the 
Opposites Attract study, but follow-up in these studies was not 
sufficient to exclude a significant upper limit of risk around the 
study estimates of zero transmissions in gay men.
Added value of this study
The second phase of the PARTNER study fills the gap in the 
evidence base for risk of HIV transmission in serodifferent gay 
couples in which the HIV-positive partner is on virally 
suppressive ART and condoms are not used. By the end of 
follow-up, 15 new HIV infections had occurred during eligible 
couple-years of follow-up, but none were phylogenetically 
linked within-couple transmissions. Thus, the linked HIV 
transmission rate during eligible couple-years was zero, 
despite 76 000 reports of condomless anal sex, with a low 
upper 95% CI limit of 0·23 per 100 couple-years of follow-up. 
Our findings provide a level of evidence on viral suppression 
and HIV transmission risk through condomless sex for gay 
men similar to that already reported for heterosexual couples.
Implications of all the available evidence
The results from the PARTNER studies in addition to evidence 
from other studies in serodifferent couples indicate that the risk 
of transmission of HIV through condomless sex in the context 
of virally suppressive ART is effectively zero for both gay men 
and heterosexual couples. These results support the U=U 
(undetectable equals untransmittable) message, as well as 
promoting the benefits of early testing and treatment.
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wished to take part in a transmission study. Serodifferent 
couples (HIV-positive men on ART with their HIV-
negative male partner) were eligible to take part if both 
partners were aged 18 years or older; the partners 
reported having penetrative sex with each other without 
condoms in the month before enrolment; the HIV-
positive partner expected to remain on ART; the partners 
expected to have sex together again in the coming 
months; and both partners agreed to take part. Partners 
signed separate informed consent forms, which included 
partner iden tification by name. Follow-up ended on 
April 30, 2018. Follow-up was stopped if the partnership 
ended, the couple moved away, or if either partner 
withdrew consent, but not for changes in use of condoms 
or ART.
The protocol,10 all informed consent forms, and 
participant information materials were submitted to and 
approved by the ethics committee (institutional review 
board [IRB] or independent ethics committee [IEC]) at 
each clinical site. Ethics approval was obtained in-country 
for all sites involved in the study. Additionally, any 
amendments to the study protocol were submitted and 
approved by each site’s ethics committee (IRB or IEC).
Procedures
Study procedures have been described previously.8 Data 
were collected at baseline and then every 4–6 months 
during study visits. Detailed information was obtained 
at baseline and each follow-up visit through self-
completed questionnaires on sociodemo graphics; self-
reported adherence to ART; frequency and type of sexual 
activity between the partners (since last visit); symptoms 
and diagnoses of other sexually transmitted infections 
(STIs); use of PrEP or post-exposure prophylaxis (PEP); 
and injection drug use. HIV-negative partners were 
asked if they had condomless sex with anyone other 
than their HIV-positive partner in the study since their 
last visit and HIV serostatus of other partners if known.
For the HIV-positive partner, ART regimen, CD4 cell 
count, and current and recent plasma HIV-1 RNA load 
were recorded on a clinical case report form at baseline 
and at each visit. The HIV-negative partner was asked 
to test for HIV every 6–12 months; a combined HIV 
antigen–antibody test was recommended to increase 
diagnostic sensitivity in early infection. Plasma HIV-1 
RNA viral load was measured in the HIV-positive partner 
according to routine care every 6–12 months using the 
local diagnostic laboratory. Results were included in the 
case report forms and submitted after each partner visit 
by the study team to the study centre.
If an HIV-negative partner became HIV-positive, 
HIV-1 pol and env sequences were obtained from the 
seroconverted partner’s HIV-1 RNA recovered from 
plasma and from the HIV-positive partner on virally 
suppressive ART’s cellular HIV-1 DNA recovered 
from peripheral blood mononuclear cells. Pol and env 
sequences were generated by Sanger sequencing (on a 
ABI 3730xl DNA Analyzer, Thermo Fisher, Warrington, 
UK)11 complemented by deep sequencing of plasma 
HIV-1 RNA by Illumina (on a MiSeq, Illumina, Essex, 
UK) in a subset with available plasma samples.12 All 
sequencing testing was done at the University of 
Liverpool (Liverpool, UK). Maximum likelihood and 
Bayesian Markov chain Monte Carlo inferences and 
their relevant statistical support were determined with 
RAxML-HCP2 version 8 and MrBayes version 3.2.6, 
respectively, as previously described.8,13
Statistical analysis
The primary analysis was estimation of the incidence 
rate of HIV transmission through condomless anal sex, 
calculated as the number of phylogenetically linked 
HIV infections (ie, transmission from the HIV-positive 
study index partner) that occurred during eligible 
couple-years of follow-up divided by eligible couple-
years of follow-up. Couple-years of follow-up were 
periods of time defined by HIV tests and corresponding 
questionnaires on sexual behaviour in the HIV-negative 
partner. These couple-years were eligible for inclusion 
in the analysis for this study if couples had condomless 
sex during the period (reported at the end of the time 
period by the HIV-negative partner, or by the HIV-
positive partner if the HIV-negative partner did not 
complete the question); PEP or PrEP was not reported 
by the HIV-negative partner during the period; the most 
recent plasma HIV-1 RNA viral load in the HIV-positive 
partner was measured to be less than 200 copies per mL 
and within the past 12 months at all points measured in 
the period; and follow-up occurred before April 30, 2018 
(the censoring date). Couple-years of follow-up could be 
ineligible for one or more reasons; the choice of primary 
reason for ineligibility was prioritised in the following 
order: (1) PEP or PrEP used; (2) HIV-negative partner 
(or the HIV-positive partner if the HIV-negative partner 
did not reply) reported no condomless sex; (3) most 
recent viral load of HIV-positive partner more than 
200 copies per mL; (4) data on sexual behaviour missing; 
(5) no viral load available in the past year for each day 
in the time period; and (6) no HIV test from the 
HIV-negative partner at the end of the time period or 
later in time. Two-sided 95% CIs for the incidence rate 
of transmission were calculated using exact Poisson 
methods. Missing data were not imputed and the 
analysis was performed only on the available data. Data 
were analysed using SAS version 9.4.
In terms of sample size calculation, the PARTNER2 
study was designed to assess whether the risk of trans-
mission in the context of virally suppressive ART was 
below an acceptably low level, defined as one infection 
per 500 couple-years of follow-up, corresponding to an 
upper limit for the two-sided 95% CI of the rate of 
within-couple HIV transmission of 0·2 per 100 couple-
years of follow-up. In the absence of linked infections, 
we determined that we needed 1770 eligible couple-years 
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of follow-up to obtain such an upper limit of the two-
sided 95% CI. On the basis of findings from PARTNER1, 
we planned to recruit 450 couples over 27 months in 
PARTNER2. Assuming a retention rate of 85%, this 
would have allowed us to accumulate 2082 couple-years 
of follow-up through PARTNER1 and PARTNER2, of 
which 85% were predicted to be eligible (based on 
interim results14) for the primary analysis.
Role of the funding source
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to all 
the data in the study and had final responsibility for the 
decision to submit for publication.
Results
Between Sept 15, 2010, and July 31, 2017, 972 gay couples 
were recruited (477 couples during PARTNER1). By the 
end of follow-up on April 30, 2018, a total of 2072 couple-
years of follow-up had been accrued (556 couple-years of 
follow-up during PARTNER1), with an estimated dropout 
rate of 25 per 100 couple-years of follow-up. Reasons for 
dropping out of the study were the couple broke up 
(213 [43%] of 499 couples), one or both partners moved 
away (33 [7%]), consent was withdrawn (54 [11%]), the 
2-year study consent expired (21 [4%]), or the couple was 
no longer eligible (ten [2%]). The reason for dropping out 
of the study was not available for 168 (34%) couples. 
479 couple-years of follow-up were ineligible for inclusion 
in the analysis for the following reasons: no condomless 
sex reported (153 [32%] of 479 couple-years of follow-up); 
use of PEP or PrEP (115 [24%]); HIV viral load data not 
available (86 [18%]); missing data on whether condomless 
sex was reported (91 [19%]); viral load in the HIV-positive 
partner more than 200 copies per mL (19 [4%]); or no 
HIV test available in the HIV-negative partner (15 [3%]).
1593 (77%) couple-years of follow-up were eligible and 
contributed by 782 couples, with 439 couple-years of 
follow-up contributed by 340 couples during PARTNER1. 
Unless otherwise stated, the following results focus on 
the 782 couples who provided eligible couple-years of 
follow-up. Median eligible years of follow-up per couple 
was 2·0 years (IQR 1·1–3·5). 1523 (96%) of the eligible 
couple-years of follow-up were during periods in which 
the most recent measure of plasma HIV-1 RNA in the 
HIV-positive partner was less than 50 copies per mL; 
the remaining 70 (4%) were during periods in which the 
most recent measure was between 50 and 200 copies 
per mL.
Baseline characteristics of the participants who 
contributed to eligible couple-years of follow-up are 
shown in table 1. Median age was 38 years (IQR 31–45) 
in HIV-negative participants and 40 years (33–46) in 
HIV-positive partners. Three trans men were included, 
one HIV negative and two HIV positive. 19 (2%) of 
782 HIV-positive and 33 (4%) of 782 HIV-negative men 
reported that they were bisexual. HIV-negative men 
reported having condomless sex with their HIV-positive 
partners for a median 1·0 years (IQR 0·4–2·9) before 
study enrolment.
At baseline, HIV-positive partners had been on ART 
for a median of 4·3 years (IQR 1·8–9·3). Self-reported 
HIV-positive 
partner (n=782)
HIV-negative 
partner (n=782)
Age (years) 40·0 (33·3–46·1) 37·6 (30·9–45·3)
Ethnicity
White 674/765 (88%) 686/767 (89%)
Black 10/765 (1%) 9/767 (1%)
Asian 14/765 (2%) 14/767 (2%)
Other 67/765 (9%) 58/767 (8%)
Education
High school or less 143/762 (19%) 144/760 (19%)
Vocational education 191/762 (25%) 176/760 (23%)
College or university 428/762 (56%) 440/760 (58%)
HIV acquisition route
Heterosexual 2/762 (<1%) NA
Homosexual 736/762 (97%) NA
Shared needles or other 
injection equipment
0/762 NA
Other 24/762 (3%) NA
Years of condomless sex* 1·0 (0·4–2·9) 1·0 (0·4–2·9)
Years on ART† 4·3 (1·8–9·3) NA
Self-reported adherence
≥90% 739/753 (98%) NA
<90% 14/753 (2%) NA
Missed ART for more than 4 consecutive days
Yes 15/762 (2%) NA
No 747/762 (98%) NA
Informed their partner if they missed doses of ART
No 26/765 (3%) NA
Yes 316/765 (41%) NA
Did not miss doses 423/765 (55%) NA
Correctly self-reported HIV load (whether undetectable or not) 
Yes 698/747 (93%) NA
No 49/747 (7%) NA
Undetectable viral load (measured, copies per mL) 
<50 754/781 (97%) NA
≥50 27/781 (3%) NA
Undetectable viral load (measured, copies per mL)
<200 774/781 (99%) NA
≥200 7/781 (<1%) NA
CD4 count (cells per µL) 
>350 730/781 (93%) NA
≤350 51/781 (7%) NA
Data are median (IQR) or n/N (%). NA=not applicable. ART=antiretroviral therapy. 
Denominators for percentages are all participants in that group who contributed 
to eligible couple-years of follow-up and provided a response to that question 
(missing data are excluded). *Data missing for 63 HIV-positive partners and 
64 HIV-negative partners. †Data missing for 43 HIV-positive partners.
Table 1: Baseline characteristics of couples eligible for the primary analysis
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adherence to ART was high, with 739 (98%) of 753 HIV-
positive partners reporting adherence of 90% or more at 
study entry. 698 [93%] of 747 HIV-positive partners 
correctly self-reported at baseline whether their viral load 
was undetectable or not. This was an underestimate by 
the HIV-positive participants: 97% had undetectable viral 
load (<50 copies per mL) and 99% had viral load of less 
than 200 copies per mL. 730 [93%] of 781 HIV-positive 
partners had a CD4 count of more than 350 cells per µL 
at baseline.
During all couple-years of follow-up, very few (37 [5%] 
of 779) of the HIV-positive partners reported that 
they missed ART for more than four consecutive days. 
For 1461 (92%) of 1593 eligible couple-years of follow-
up, adherence was more than 90% (not reported 
for 96 [6%] couple-years of follow-up) according to 
the HIV-positive partner. Most HIV-positive partners 
were on ART regimens containing three or more 
drugs (1470 [92%] couple-years of follow-up), with fewer 
HIV-positive partners taking regimens containing 
two drugs (73 [5%] couple-years of follow-up), or ART 
monotherapy (34 [2%] couple-years of follow-up). For 
the remaining 1% (16 couple-years of follow-up), 
the HIV-positive partners were either in a blinded 
clinical trial group or the ART regimen was unknown. 
For a quarter (396 [25%]) of eligible couple-years of 
follow-up, the HIV-positive partners were taking 
protease-inhibitor based regimens, for 47% (754 couple-
years of follow-up) they were taking non-nucleoside 
reverse transcriptase inhibitor-based regimens, for 
26% (408 couple-years of follow-up) they were taking 
integrase inhibitors, and for the remaining 2% 
(35 couple-years of follow-up) they were taking other or 
not reported regimens.
During follow-up (table 2), 185 (24%) of 779 HIV-
negative men and 214 (27%) of 779 HIV-positive men 
reported an STI since their last visit. Couples reported 
having condomless sex 6090 times during eligible periods 
when an STI was present. 288 (37%) of 777 HIV-negative 
partners reported condomless sex with other partners. 
Few HIV-negative partners (28 [4%] of 775) reported 
injecting drugs during follow-up. In total, couples 
reported having condomless anal sex approximately 
76 088 times during eligible couple-years of follow-up 
(figure 1). The median number of times couples had 
condomless sex was 43 times per year (IQR 19–75). 
Condomless sex was reported 2–10 times per 4-month 
period in 657 (41%) of 1593 eligible couple-years of follow-
up, 21–40 times per 4-month period in 408 (26%) eligible 
couple-years of follow-up, and between 11 and 20 times 
per 4-month period in 332 (21%) eligible couple-years of 
follow-up (appendix).
Figure 1 shows data on prevalence of the types of 
condomless penetrative sex (with the HIV-positive 
partner) reported by the HIV-negative partner. By 
definition, couples contributing eligible couple-years of 
follow-up reported anal sex without condoms during 
follow-up. Overall, 577 (75%) of 773 HIV-negative partners 
reported that they had receptive anal sex without 
ejaculation during follow-up, 436 (56%) of 776 reported 
HIV-positive 
partner (n=782)
HIV-negative 
partner (n=782)
Time in the study (years) 2·0 (1·1–3·5) 2·0 (1·1–3·5)
STIs* 214/779 (27%) 185/779 (24%)
Syphilis 69/779 (9%) 54/779 (7%)
Gonorrhoea 85/779 (11%) 84/779 (11%)
Chlamydia 79/779 (10%) 66/779 (8%)
Herpes 10/779 (1%) 10/779 (1%)
Chronic herpes 7/779 (1%) 5/779 (1%)
Warts 22/779 (3%) 20/779 (3%)
LGV 9/779 (1%) 4/779 (1%)
Other STI 24/779 (3%) 23/779 (3%)
Not specified 4/779 (1%) 3/779 (<1%)
Condomless sex with other partners
Yes NA 288/777 (37%)
No NA 489/777 (63%)
Condomless sex with other HIV-positive partners†
Yes NA 249/777 (32%)
No NA 528/777 (68%)
Condomless sex acts‡ 
per year
41·3 
(17·6–72·7)
43·4  
(19·2–75·1)
Total number of condomless 
sex acts during eligible CYFU‡
73 674 76 088
Missed ART for more than 4 consecutive days
Yes 37/779 (5%) NA
No 742/779 (95%) NA
Injected non-prescription drugs
Yes 42/779 (5%) 28/775 (4%)
No 737/779 (95%) 747/775 (96%)
CYFU with reported frequency of condomless sex per month of§
Less than once 335/1593 (21%) 312/1593 (20%)
1–2 times 222/1593 (14%) 236/1593 (15%)
3–4 times 310/1593 (19%) 329/1593 (21%)
5–8 times 434/1593 (27%) 439/1593 (28%)
More than 8 times 227/1593 (14%) 240/1593 (15%)
Not reported or missing 64/1593 (4%) 38/1593 (2%)
Data are median (IQR) or n/N (%), unless othewise specified. Denominators for 
percentages are all participants in that group who contributed to eligible 
couple-years of follow-up and provided a response to that question (missing data 
are excluded), unless otherwise specified. Missing data are less than 1% for all 
variables. STIs=sexually transmitted infections. LGV=lymphogranuloma venereum. 
NA=not applicable. CYFU=couple-years of follow-up. ART=antiretroviral therapy. 
*Participants who reported an STI (excluding HIV) since the last visit were asked 
whether it was syphilis, gonorrhoea, chlamydia, acute genital herpes, chronic genital 
herpes, LGV, or other. Participants who replied “yes” to the question “Since your last 
visit, have you had an STI?” but did not reply to the question “If yes, which STI?” were 
categorised as “not specified”. †Only participants who reported condomless sex with 
other partners were asked this question. For this variable, missing is treated as “no” 
and the denominator to calculate the percentages is the number of participants who 
answered the question on whether they had “condomless sex with other partners” 
(n=777). ‡Only sex acts within couples are included. §The denominator is the total 
group-specific eligible CYFU (1593 CYFU). Note numerators and percentages do not 
add up to 1593 and 100%, respectively, because of rounding.
Table 2: Characteristics during all follow-up of couples eligible for the 
primary analysis
See Online for appendix
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receptive anal sex with their partner ejaculating inside, 
and 709 (91%) of 777 reported insertive anal sex.
15 of the initially HIV-negative partners became 
HIV-1 positive during eligible follow-up, but there 
were no within-couple phylogenetically linked trans-
missions. 13 of the 15 individuals provided information 
about their presumed source of HIV infection, of 
whom ten (77%) reported recent condomless sex 
with men other than their study partner. Samples 
collected from the two partners of each of these 
15 couples for sequencing were a median of 0 months 
apart (IQR 0·0–5·9). Viral sequences were recovered 
success fully from all couples (15 [100%] of 15 couples for 
pol genes and 13 (87%) of 15 for env genes). All new 
infections were phylogenetically unrelated to the initially 
HIV-positive partner’s virus (figure 2 and appendix). 
Viral haplotypes derived from deep sequencing data of 
plasma samples from HIV-negative partners from 
five (33%) of the 15 couples confirmed the lack of 
linkage, since all viral haplotypes in the seroconverter 
samples were phylogenetically unrelated to the virus 
from their partners. All 15 partners who were the initially 
HIV-positive partner had subtype B infection according 
to pol gene subtyping; six of the 15 seroconverting 
partners acquired non-B infections (subtypes C, A1, 
CRF29_BF, CRF60_BC, and two partners acquired 
CRF14_BG infections, respectively).
With no linked transmissions, the estimated rate for 
transmission through condomless anal sex when the 
positive partner on ART had HIV viral load less than 
200 copies per mL was zero, with an upper 95% CI limit 
of 0·23 per 100 couple-years of follow-up (equivalent 
to one transmission per 435 years of condomless sex). 
Figure 1 reports the rates of within-couple HIV trans-
mission per 100 eligible couple-years of follow-up by 
sexual behaviour reported by the HIV-negative partner. 
For receptive anal sex with ejaculation the upper 
95% CI limit was 0·57 per 100 couple-years of follow-up 
(equivalent to one transmission per 175 years of 
condomless sex). Figure 3 gives the upper bounds of the 
95% CI around the estimate of zero transmissions for 
gay men and heterosexual couples achieved by the end of 
PARTNER18 and for gay men by the end of PARTNER2.
There were fewer eligible couple-years of follow-
up during periods when the HIV-positive partner 
(135 couple-years of follow-up) or the HIV-negative 
partner (116 couple-years of follow-up) reported an STI, 
but no linked transmissions were reported. The 
upper 95% CI limit to the transmission estimate for 
periods with an STI in the HIV-negative partner was 
3·17 per 100 couple-years of follow-up. Only 8 couple-
years of follow-up of condomless sex were reported 
when the HIV-positive partner was in the first 6 months 
of taking ART.
Six additional seroconversions in HIV-negative partners 
took place outside eligible couple-years of follow-up. 
Reasons for the ineligibility of the couple-years in which 
these seroconversions occurred were no questionnaire 
containing sexual behaviour at the end of the period by the 
HIV-negative or HIV-positive partner (n=3); HIV-negative 
partner reported no condomless sex with the HIV-positive 
partner (n=1); use of PEP reported during the period 
when the infections occurred (n=1); and no HIV viral 
load measurement for the HIV-positive partner in the 
past year (n=1). The six newly infected partners were last 
seen 2 months, 6 months (n=2), 9 months, 13 months, 
and 16 months before sero conversion was recorded, 
respectively. Phylogenetic analysis showed that these 
transmissions were not linked to the HIV-positive partner 
on virally suppressive ART.
19·3 couple-years of follow-up were not eligible 
because of viral load in the HIV-positive partner being 
higher than 200 copies per mL for at least 1 day during 
the period (range 202–170 000 copies per mL), but all 
other criteria were met. During couple-years of follow-
up with viral load higher than 200 copies per mL, people 
Figure 1: Rate of within-couple HIV transmission through condomless sex according to sexual behaviour reported by the HIV-negative partner
STI=sexually transmitted infection. NA=not applicable. *Estimated using the exact Poisson method. †Numerator is the number of HIV-negative men within the 
eligible couples ever reporting that specific sexual act and denominator is the group-specific number of HIV-negative participants who contributed eligible 
couple-years of follow-up. ‡Refers to STIs (excluding HIV) self-reported by the HIV-negative partner.
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reported having condomless sex a total of 810 times 
with zero phylogenetically linked transmissions. For the 
majority of these days, the most recent viral load in the 
HIV-positive partner was less than 200 copies per mL 
(12·3 couple-years of follow-up, estimated 513 sex acts), 
for 4·5 couple-years of follow-up the most recent viral 
load was between 200 and 1000 copies per mL (estimated 
180 sex acts), and only for a minority of days the most 
recent viral load was higher than 100 000 copies per mL 
(0·23 couple-years of follow-up, estimated 31 sex acts).
Discussion
Our findings provide conclusive evidence that the risk 
of HIV transmission through anal sex when HIV viral 
load is suppressed is effectively zero. Among the 
782 serodifferent gay couples followed for almost 
1600 eligible couple-years of follow-up, which included 
more than 76 000 reports of condomless sex, we found 
zero cases of within-couple HIV transmission. In the 
absence of ART, on the basis of the frequency and type 
of sex, for receptive condomless anal sex acts alone 
approximately 472 transmissions (95% CI 83–714) would 
have been expected.15 Our results give equivalence of 
evidence for gay men as for heterosexual couples and 
indicate that the risk of HIV transmission when HIV 
viral load is suppressed is effectively zero for both anal 
and vaginal sex.
For gay couples at the end of PARTNER1, the rate of 
within-couple transmission was zero, but this estimate 
was less precise than that for heterosexual couples 
because of the lower number of couple-years of follow-
up accrued (0·84 per 100 couple-years of follow-up, 
equivalent to one transmission per 119 years of 
condomless sex in gay couples vs 0·46 per 100 couple-
years of follow-up, or one infection per 217 years of 
condomless sex in heterosexual couples).8 By extending 
the study in PARTNER2 and increasing the couple-years 
of follow-up accumulated in gay men, the upper bound 
of the 95% CI around the estimate of zero transmissions 
was reduced compared with that reported by the end of 
PARTNER1. The upper limit of the 95% CI is now 
0·23 for anal sex, which is equivalent to one transmission 
Figure 2: Phylogenetic tree of pol and env sequences from nine couples with 
subtype B infection
Bayesian Markov Chain Monte-Carlo inference (012313+I+G+F). Branch length is 
proportional to the genetic distance and line weight is proportional to the 
posterior probability. (A) Partners’ (initially HIV-positive partners and 
seroconverters) sequences are in blue and found phylogenetically unlinked to 
viruses recovered from their putative transmitters, with a median pairwise genetic 
distance of 0·069 (IQR 0·057 to 0·076) and pairwise genetic distances consistently 
greater than 0·040. Positive control sequences comprised replicate sequences 
from study partners and sequences from confirmed transmission pairs obtained in 
a separate study.13 The positive control sequences show pairwise genetic 
distance 0·004 (IQR <0·000 to 0·007) and always closely linked on monophyletic 
clusters with posterior probabilities more than 0·98 (red and orange clusters in 
the phylogenetic tree). Control sequences comprised the ten closest sequences 
identified through BLAST searches of GenBank. (B) Partners’ (initially HIV-positive 
partners and seroconverters) sequences are in blue and found phylogenetically 
unlinked to viruses recovered from their putative transmitters, with a median 
pairwise genetic distance of 0·14 (IQR 0·125 to 0·169). Positive control sequences 
comprised replicate sequences from study partners (in red). The positive control 
sequences show pairwise genetic distance 0·001 (IQR <0·001 to 0·014) and always 
linked on monophyletic clusters with posterior probabilities equal to 1·00 
(red clusters in the phylogenetic tree). Control sequences comprised the 
ten closest sequences identified through BLAST searches of GenBank.
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per 435 years of condomless sex, such that the evidence 
for gay men is now stronger than that for heterosexual 
couples in PARTNER1, thus achieving the aim of the 
PARTNER2 study.
Unlike other studies on HIV transmission, we only 
recruited couples that had already chosen not to use 
condoms and in the primary analysis we only included 
periods when condoms were not used and with no use of 
PrEP or PEP by the HIV-negative partner. We found no 
linked transmissions across all types of sexual behaviour 
and during periods when the HIV-positive or HIV-negative 
partner reported an STI. A quarter of HIV-positive and 
HIV-negative partners reported having an STI during 
follow-up, and although there were fewer couple-years of 
follow-up during these periods (116 couple-years of follow-
up), no linked transmissions occurred. Similar to our 
findings, no HIV transmissions occurred during periods 
in which STIs were reported (21 couple-years of follow-up) 
in the Opposites Attract study.9 We also reported on 
19 couple-years of follow-up that were not eligible for 
inclusion in the primary analysis because the HIV viral 
load of the HIV-positive partner was higher than 
200 copies per mL, but all other criteria for eligibility were 
met. During this time, no linked transmissions occurred 
despite couples having sex 810 times without condoms.
One limitation of the study was that most couples had 
been having sex without condoms for more than 6 months 
before study entry. Although there is little evidence that 
some individuals might be more susceptible to early 
acquisition of HIV infection, we were unable to determine 
risk of HIV transmission in very new partnerships. 
We also acknowledge that most HIV transmission is in 
young people (aged <25 years). In our study, recruited 
HIV-negative partners were predominantly of white 
ethnicity (89%), with a median age of 38 years. Most HIV-
positive partners had been on virally suppressive ART for 
several years, so we had limited couple-years of follow-up 
during the initial months of ART. Data from the Partners 
PrEP study suggest that a residual risk of HIV 
transmission persists during the first 6 months of ART 
because of incomplete viral suppression in blood and 
genital compartments.16 However, in that study, all three 
ART-exposed phylogenetically linked HIV transmission 
events in the first 6 months occurred before the HIV-
positive partner achieved complete HIV viral suppression 
in blood. This observation suggests that residual trans-
mission risk observed in the first 6 months was related to 
lack of suppression in blood rather than any genital tract 
viraemia. It is therefore important after starting ART to 
use preventive measures such as consistent condom use 
or PrEP17 until viral load suppression in blood is fully and 
sustainably achieved.
It is well recognised that HIV-positive people on 
ART with suppressed viral load in blood can have inter-
mittent shedding and detectable HIV RNA in semen and 
other genital tract fluids. HIV RNA in semen has been 
detected in 6–8% of men with suppressed HIV-1 RNA 
concentrations in blood in the absence of STIs.18,19 In the 
Partners PrEP study, seminal HIV-1 RNA was detected 
in 11%, 5%, and 6% of samples collected after 0–3 months, 
4–6 months, and more than 6 months on ART, 
respectively.20 However, the scientific detection of small 
amounts of HIV RNA in semen does not appear to 
correlate with risk of HIV transmission if plasma viral 
load is suppressed. This finding might be because the 
virus present is not whole virus, is not replication 
competent, or is present at insufficient levels to cause 
transmission.21 In the Partners in Prevention study, no 
transmissions occurred from individuals with detectable 
HIV genital viral load, but suppressed plasma viral load, 
to their HIV-negative partners.22
The effectiveness of ART in preventing HIV trans-
mission is dependent on maintaining full virological 
suppression in plasma. In the HPTN 052 trial, the 
overall risk reduction through ART initiation was 93%,7 
but of the eight linked partner infections diagnosed after 
the index case started ART, transmissions occurred 
during a period of detectable HIV viraemia in plasma in 
index cases.23 Four transmissions occurred shortly before 
or after the index case started ART with viral load 
measurements at the nearest timepoint ranging from 
48 316 copies per mL to more than 750 000 copies per mL 
in the index case. The other four linked transmissions 
occurred between 1062 and 2162 days after the index 
case started ART, all of whom had documented ART 
failure, and in the three cases who remained in follow-
up, the last HIV viral load measurement before the 
estimated infection date was more than 200 copies 
per mL.23 These findings emphasise the importance of 
regular monitoring to ensure HIV viral load remains 
suppressed and supporting HIV-positive people with 
long-term adherence. Our study reflected current HIV 
viral load testing practices in Europe with 6 monthly or 
even annual viral load testing once individuals are 
established on ART with good adherence, as in our 
cohort. Once an individual is virally suppressed on ART, 
the risk of viral load rebound in the context of good 
adherence is very low. Data from the large UK CHIC 
cohort showed that rates of viral rebound in HIV-positive 
Figure 3: Upper 95% CI limit around estimated rate of zero HIV transmissions 
through penetrative sex (vaginal or anal) at the end of PARTNER18 and 
PARTNER2
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people on ART were low (7·8 per 100 person-years), and 
that 30% of people with rebound achieved virological 
resuppression without a change in ART regimen.24 In 
gay men older than 45 years, the rate of viral rebound 
reached a plateau of 1% per year, suggesting that in high-
income settings at least, most people on ART will not 
have virological failure over their lifetime.24 In our 
study, accurate self-knowledge of viral load status was 
very high, with 93% of HIV-positive partners correctly 
self-reporting viral load status at baseline. Participants 
underestimated their suppressed viral load status, 
however, as 97% actually had a suppressed viral load of 
less than 50 copies per mL and 99% had a viral load of 
less than 200 copies per mL.
Despite all the concerns about potential risks, there has 
not been a single verified case of HIV transmission in 
the context of complete virally suppressive ART reported 
in the literature. By contrast, there have been many large 
prospective studies specifically designed to find cases of 
HIV transmission when HIV-positive partners were 
virally suppressed that were unable to do so.1–4,6–9 A case 
report of possible HIV transmission in a serodifferent 
gay couple despite virally suppressive ART in the HIV-
positive partner25 was published in 2008, a few months 
after the release of the Swiss Statement.26 However, this 
case study did not meet the necessary conditions required 
for establishing that this was a linked transmission in the 
context of virally suppressive ART. These conditions are 
documentation of fully virally suppressive ART during 
which time the couple had condomless sex together, a 
verifiable negative HIV test in the HIV-negative partner 
at the start of the documented period of viral load 
suppression, and phylogenetic linkage of viruses from 
both partners.27 In this case report, there was a lack of 
documentation of a negative HIV test in the HIV-negative 
partner at the start of the period of viral load suppression 
in the HIV-positive partner, because the negative result 
was based only on the participant’s recollection of an 
undocumented, anonymous HIV test obtained 5 years 
earlier.27 Because the HIV-negative partner had sex with 
the index case during the first weeks of ART, it is 
therefore likely that HIV transmission occurred before 
viral load was suppressed in the index case.
Knowledge about the impact of viral load suppression on 
transmissibility has been slow to filter from the scientific 
community to the wider community. In 2016, Landovitz 
and colleagues28 reported that of 1809 participants in the 
ACTG A5257 study (a drug comparison study) who had 
been on ART for at least 48 weeks, with 91% with HIV RNA 
less than 50 copies per mL, 38% thought that they were 
highly infectious and the majority (90%) thought that they 
were somewhat infectious. This study was reported 16 years 
after data from the Rakai Project Study,1 5 years after the 
HPTN 052 trial,6 and 2 years after the PARTNER1 interim 
results were released.14 To improve dissemination of the 
scientific knowledge in this area, in 2016 the Prevention 
Access Campaign launched the U=U (undetectable equals 
untransmittable) campaign, based on the statement: a 
person living with HIV who has undetectable viral load 
does not transmit HIV to their partners.29,30 This statement 
has been endorsed to date by more than 780 HIV 
organisations from 96 countries, including by leading 
scientific and medical organisations.
However, U=U is only easy to apply when HIV-positive 
people have access to testing, effective treatment, viral 
load monitoring to levels of less than 200 copies per mL, 
and support to reach and maintain viral suppression. 
Even in high-income settings there are differences in 
rates of viral suppression. For example, the HIV Care 
Continuum in the USA indicated that of the 1·1 million 
people living with HIV in 2014, 85% were diagnosed, 
but only 49% were virologically suppressed.31 A sustained 
effort is required to increase rates of testing and HIV 
diagnosis with early initiation of ART and full support to 
maintain high levels of adherence.
The results from the PARTNER studies support wider 
dissemination of the message of the U=U campaign that 
risk of transmission of HIV in the context of virally 
suppressive ART is zero. This dissemination is necessary 
to promote the benefits of early testing and treatment 
and to tackle stigma, discrimination, and criminalisation 
laws that continue to affect HIV-positive people.
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